|
1) Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009; 137: 102-7
|
|
|
|
2) 循環器病の診断と治療に関するガイドライン研究班. 心房細動治療(薬物)ガイドライン. Circ J. 2008; 72 Suppl IV: 1581-638
|
|
|
|
|
3) 循環器病の診断と治療に関するガイドライン研究班. 循環器疾患における抗凝固・抗血小板療法に関するガイドライン｣(2009年改定版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_d.pdf
|
|
|
|
|
|
4) The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010; 31: 2369-429
|
|
|
|
|
|
5) Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrilla-tion: a systematic review. Am J Med. 2010; 123: 638-45
|
|
|
|
|
|
6) Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51, and Erratum in: N Engl J Med. 2010; 363: 1877
|
|
|
|
|
|
7) Wallentin L, Yusuf S, Ezekowitz MD, et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376: 975-83
|
|
|
|
|
|
8) Diener HC, Connolly SJ, Ezekowitz MD, et al. RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010; 9: 1157-63
|
|
|
|
|
|
9) Ezekowitz MD, Wallentin L, Connolly SJ, et al; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010; 122: 2246-53
|
|
|
|
|
|
10) Hori M, Connolly SJ, Ezekowitz MD, ert al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub-analysis in Japanese population in RE-LY trial. Circ J. 2011; 75: 800-5
|
|
|
|
|
11) Mahaffey KW, Fox KAA. Stroke Prevention Using the Oral Direct Factor Xa inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation(ROCKET AF). http://sciencenews.myamericanheart.org/pdfs/ROCKET_AF_pslides.pdf
|
|
|
|
|
|
12) Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investi-gators. Apixaban in patients with atrial fibrilla-tion. N Engl J Med. 2011; 364: 806-17
|
|
|
|
|
|
13) 大村剛史, 池上幸三郎, 堀 克彦, 他. 抗凝固薬ダビガトランエテキシラートのA-Vシャントモデルにおける抗血栓および出血に対する作用ならびに抗血栓作用に対するビタミンKの影響. Pharma Medica. 2011; 29: 137-42
|
|
|
|
|
14) Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989; 134: 1087-97
|
|
|
|
|
|
15) Stangier J. Clnical pharmacokinetics and phar-macodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47: 285-95
|
|
|
|
|
|
16) Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagu-lant therapy (RE-LY) trial. Circulation. 2011; 123: 2363-72
|
|
|
|
|
|
17) Toyoda K, Yasaka M, Iwade K, et al; Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multi-center, observational study. Stroke. 2008; 39: 1740-5
|
|
|
|
|
|
18) Toyoda K, Yasaka M, Uchiyama S, et al; Bleeding with Antithrombotic Therapy (BAT) Study Group. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Anti-thrombotic Therapy (BAT) Study. Stroke. 2010; 41: 1440-4
|
|
|
|
|
|
19) Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151: 297-305
|
|
|
|
|
|
20) Ogawa S, Koretsune Y, Yasaka M, et al. Antithrombotic therapy in atrial fibrillation: Evaluation and positioning of new oral anti-coagulant agents. Circ J. 2011; 75: 1539-47
|
|
|
|
|
|
21) Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64: 292-303
|
|
|
|
|